Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Saved in:
| Title: | Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. |
|---|---|
| Authors: | Shemesh CS; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Chan P; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Shao H; Safety Science, F. Hoffmann-La Roche Ltd., Beijing, China., Xu DZ; Product Development Oncology, F. Hoffmann-La Roche Ltd., Shanghai, China., Combs D; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Vadhavkar S; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA., Bruno R; Clinical Pharmacology, Genentech-Roche, Marseille, France., Wu B; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA. |
| Source: | Liver cancer [Liver Cancer] 2021 Jun 10; Vol. 10 (5), pp. 485-499. Date of Electronic Publication: 2021 Jun 10 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
